Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Revenue (2016 - 2023)

Spyre Therapeutics' Revenue history spans 7 years, with the latest figure at $688000.0 for Q2 2023.

  • For Q2 2023, Revenue rose 10.08% year-over-year to $688000.0; the TTM value through Mar 2024 reached $688000.0, down 40.94%, while the annual FY2023 figure was $886000.0, 61.96% down from the prior year.
  • Revenue reached $688000.0 in Q2 2023 per SYRE's latest filing, up from $198000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $12.0 million in Q2 2021 to a low of $168000.0 in Q4 2022.
  • Average Revenue over 3 years is $3.4 million, with a median of $688000.0 recorded in 2023.
  • Peak YoY movement for Revenue: crashed 98.55% in 2022, then grew 10.08% in 2023.
  • A 3-year view of Revenue shows it stood at $3.6 million in 2021, then tumbled by 95.39% to $168000.0 in 2022, then skyrocketed by 309.52% to $688000.0 in 2023.
  • Per Business Quant, the three most recent readings for SYRE's Revenue are $688000.0 (Q2 2023), $198000.0 (Q1 2023), and $168000.0 (Q4 2022).